Rigel Pharmaceuticals (RIGL) Cash from Operations (2010 - 2026)

Rigel Pharmaceuticals' Cash from Operations history runs 17 years deep, the most recent figure standing at 2725000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations rose 405.15% year-over-year to 2725000.0 in Q1 2026; TTM through Mar 2026 was 79273000.0, a 122.73% increase from a year earlier, with the FY2025 full-year figure at 75655000.0, up 140.4% from the prior year.
• Cash from Operations declined to 2725000.0 in Q1 2026 per RIGL's latest filing, from 21980000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 30537000.0 in Q2 2025 and bottomed at 25637000.0 in Q1 2022.
• The 5-year median for Cash from Operations is 893000.0 (2025), against an average of 1785294.12.
• Across the five-year window, Cash from Operations sank 123.38% in 2022 and surged 10011.59% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 21909000.0 in 2022, then surged by 71.52% to 6240000.0 in 2023, then soared by 332.42% to 14503000.0 in 2024, then jumped by 51.55% to 21980000.0 in 2025, then slumped by 87.6% to 2725000.0 in 2026.
• Per Business Quant, the three latest RIGL Cash from Operations figures stand at 2725000.0 (Q1 2026), 21980000.0 (Q4 2025), and 24031000.0 (Q3 2025).